Study Comparing Induction Nivolumab-Ipilimumab Followed by Chemoradiation Versus Chemoradiation Alone for Advanced Cervical Cancer
Led by Hospital Israelita Albert Einstein · Updated on 2024-01-05
112
Participants Needed
14
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for women with locally advanced cervical cancer, specifically adenocarcinoma or squamous cell carcinoma at certain stages FIGO Stage IB2-IB3 node positive or Stage IIB-IVA. The study compares standard cisplatin-based chemoradiation with a combination of immunotherapy drugs nivolumab and ipilimumab followed by chemoradiation. This Phase II trial aims to assess 3-year progression-free survival among participants.
Participants are randomly assigned to one of two groups. One group receives standard radiation therapy targeting 45 Gy in 25 fractions with concurrent weekly cisplatin or carboplatin chemotherapy. The other group receives 4 cycles of induction immunotherapy with nivolumab and ipilimumab every 3 weeks, followed by the same radiation and chemotherapy regimen combined with nivolumab every 2 weeks. The study includes detailed treatment schedules and dosing for all therapies.
During the study, participants will undergo regular evaluations including imaging to assess lesions, health-related quality of life assessments, and monitoring for treatment-related toxicities. Researchers will measure outcomes such as 3-year progression-free survival, overall survival, response rates, and quality of life changes. The total follow-up period includes assessments up to three years after treatment to monitor effectiveness and safety.
CONDITIONS
Brief Title
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Research Team
D
Diogo Bugano, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with cervical adenocarcinoma or squamous carcinoma, FIGO Stage IB2-IB3 node positive or Stage IIB-IVA
No prior chemotherapy, immune checkpoint inhibitors, or radiotherapy for cervical cancer
WHO/ECOG performance status of 0-1
At least one lesion qualifying as a RECIST 1.1 Target Lesion at baseline
You will not qualify if you...
Diagnosis of small cell (neuroendocrine) cervical cancer
Planning fertility-sparing treatment
Previous hysterectomy
Evidence of metastatic disease including lymph nodes ≥15 mm above L1 or outside planned radiation field
History of allogeneic organ transplantation
Active or prior autoimmune or inflammatory disorders
Uncontrolled intercurrent illness
History of another primary malignancy or active primary immunodeficiency
Active infection
Laboratory abnormalities including low white blood cells, neutrophils, platelets, hemoglobin, high creatinine, elevated liver enzymes, high bilirubin (with exceptions), or positive hepatitis B or C tests
Use of systemic corticosteroids or immunosuppressive drugs within 14 days before starting treatment
Pregnant or breastfeeding women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Induction Immunotherapy
Duration - Approximately 12 weeks
Participants receive 4 cycles of induction immunotherapy with nivolumab and ipilimumab every 3 weeks before starting chemoradiation.
4 visits every 3 weeks (in-person)
Chemoradiation Treatment
Duration - Approximately 5 to 6 weeks
Participants undergo traditional radiation therapy with concurrent weekly chemotherapy; those in the immunotherapy arm also receive nivolumab every 2 weeks during this period.
Weekly visits for chemoradiation and biweekly visits for nivolumab (in-person)
Post-treatment Follow-up
Duration - Up to 3 years
Participants are monitored for treatment outcomes, including response and side effects, with assessments continuing up to 3 years.
Follow-up visits scheduled periodically over 3 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase III Study of UCB4594, a Monoclonal Antibody Targeting HLA-G, Alone and With Other Cancer Treatments in Adults With Advanced Solid Tumors
Radiomic MRI Model to Predict Response to Chemoradiotherapy in Locally Advanced Cervical Cancer
A Retrospective Multicenter Study Using Pelvic MRI Data
Phase 1 Study Evaluating Sigvotatug Vedotin Alone and with Pembrolizumab, With or Without Chemotherapy, in Adults With Advanced Solid Tumors
Evaluating Sofetabart Mipitecan LY4170156 Safety, Tolerability, and Preliminary Efficacy in Adults With Selected Advanced Solid Tumors
Exploring Enlonstobart Combined With Chemotherapy and Radiotherapy After Induction Therapy in Women With Locally Advanced Cervical Cancer
Study of Adjuvant Chemotherapy After Neoadjuvant Chemotherapy and Surgery in Women with Locally Advanced Cervical Cancer Not Meeting NCCN Adjuvant Treatment Guidelines
Phase 3 Study Comparing Standard and Hypofractionated IMRT Radiation with Chemotherapy
for High-Risk Cervical Cancer After Radical Hysterectomy
Randomized Study of Concurrent Chemoradiotherapy With or Without Adjuvant Chemotherapy for Advanced Cervical Cancer Using Intensity-Modulated Radiation and 3D Afterloading Based on 2018 FIGO Staging
Study Comparing Self-Sampling and Clinician-Sampling HPV DNA Tests for Cervical Cancer Screening in Women Aged 30 to 69
Study Using Near-Infrared Fluorescence Imaging and Indocyanine Green to Guide Surgery for Cervical Cancer Lymph Node Metastasis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
R Wendel Naumann, Antoine Hollebecque, Tim Meyer...
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration